You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Estrogen/progesteron receptor positive tumor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor Trial in Gent, Leuven, Liège (Abemaciclib, Letrozole)

Not yet recruiting
  • Low Grade Serous Ovarian Carcinoma
  • Adult Type Granulosa Cell Tumor
  • Gent, Oost-Vlaanderen, Belgium
  • +2 more
May 12, 2023

Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary Trial in Brescia, Genova (Letrozole tablets, carboplatin

Recruiting
  • Carcinoma, Ovarian Epithelial
  • Low Grade Serous Adenocarcinoma of Ovary
  • Letrozole tablets
  • carboplatin AUC 5 and paclitaxel 175 mg/m2
  • Brescia, BS, Italy
  • +1 more
Oct 26, 2022

Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor Trial in São Paulo (Tamoxifen)

Active, not recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Tampa, Florida
  • +1 more
Jan 13, 2023

Breast Cancer Trial in Sarasota, Nashville (AC699)

Recruiting
  • Breast Cancer
  • Sarasota, Florida
  • +1 more
Jan 3, 2023

Breast Cancer, Brain Metastases Trial in New York (Brain Imaging with 18F-FES)

Not yet recruiting
  • Breast Cancer
  • Brain Metastases
  • Brain Imaging with 18F-FES
  • New York, New York
    New York-Presbyterian/Weill Cornell Medical Center
Oct 2, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Breast Cancer Stage IV Trial in Irvine (Gallium-68)

Recruiting
  • Breast Cancer Stage IV
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
May 26, 2023

Estrogen Receptor Positive Breast Cancer Trial in Edmonton (Estradiol)

Active, not recruiting
  • Estrogen Receptor Positive Breast Cancer
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Feb 1, 2023

Assessed by 18F-FES PET/CT in MBC With ER-positive Primary Tumor

Recruiting
  • Breast Cancer
    • Shanghai, Shanghai, China
      Biyun Wang, MD
    Apr 5, 2023

    Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jun 12, 2023

    Breast Cancer Trial in Beijing, Zhengzhou, Changsha (EG017)

    Not yet recruiting
    • Breast Cancer
    • Beijing, Benjing, China
    • +2 more
    Dec 30, 2022

    Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

    Active, not recruiting
    • Breast Neoplasms
    • Chuo Ku, Japan
    • +1 more
    Dec 19, 2022

    Blood and Tumor Samples From Advanced or Metastatic Estrogen

    Active, not recruiting
    • Advanced Breast Carcinoma
    • +8 more
    • Biopsy
    • +2 more
    • Scottsdale, Arizona
    • +2 more
    Jan 3, 2023

    Breast Cancer Trial in Orange City (ARV-471 (PF-07850327), Palbociclib, Letrozole)

    Recruiting
    • Breast Cancer
    • ARV-471 (PF-07850327)
    • +2 more
    • Orange City, Florida
      Mid Florida Hematology and Oncology Center
    Jun 8, 2023

    Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 Trial in San Francisco (Pembrolizumab,

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • Prognostic Stage IV Breast Cancer AJCC v8
    • Pembrolizumab
    • +2 more
    • San Francisco, California
      University of California, San Francisco
    Jan 5, 2023

    HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

    Recruiting
    • HER2-positive Breast Cancer
    • +17 more
    • ALX148
    • Fam-Trastuzumab Deruxtecan-Nxki
    • Chicago, Illinois
    • +1 more
    May 19, 2023

    Metastatic Breast Cancer Trial (Elacestrant)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Oct 24, 2022

    Advanced or Metastatic Breast Cancer Trial in Nashville (AND019 PO QD)

    Not yet recruiting
    • Advanced or Metastatic Breast Cancer
    • AND019 PO QD
    • Nashville, Tennessee
      Sarah Cannon Research Institute
    Jul 19, 2022

    Breast Cancer Trial in Denver, Sarasota, Nashville (AC682)

    Recruiting
    • Breast Cancer
    • Denver, Colorado
    • +4 more
    Dec 12, 2022

    Breast Cancer, Breast Cancer, Early-Onset Trial (Giredestrant, Tamoxifen)

    Not yet recruiting
    • Breast Cancer
    • Breast Cancer, Early-Onset
    • (no location specified)
    Jan 18, 2023

    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

    Active, not recruiting
    • Estrogen Receptor-positive Breast Cancer
    • +5 more
    • PI3K inhibitor BYL719
    • +3 more
    • Boston, Massachusetts
    • +1 more
    Oct 14, 2022

    Recurrence Score on Adjuvant Treatment Decisions in Breast

    Recruiting
    • Breast Cancer Female
      • Tübingen, BW, Germany
        Department for Women's Health
      Nov 4, 2022

      Estrogen Receptor Positive Breast Cancer, Breast Cancer Trial in Houston (ESTRING, Replens)

      Recruiting
      • Estrogen Receptor Positive Breast Cancer
      • Breast Cancer
      • Houston, Texas
        Houston Methodist Cancer Center
      Nov 18, 2022

      Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 Trial in United States (drug, other, biological)

      Suspended
      • Metastatic Breast Carcinoma
      • Stage IV Breast Cancer AJCC v6 and v7
      • Corona, California
      • +6 more
      Sep 28, 2022

      Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Houston (Radiation Therapy, Therapeutic

      Active, not recruiting
      • Estrogen Receptor Positive
      • +3 more
      • Radiation Therapy
      • Therapeutic Conventional Surgery
      • Houston, Texas
        M D Anderson Cancer Center
      Jun 14, 2022